201 related articles for article (PubMed ID: 28989100)
21. New insights into the pharmacogenomics of antidepressant response from the GENDEP and STAR*D studies: rare variant analysis and high-density imputation.
Fabbri C; Tansey KE; Perlis RH; Hauser J; Henigsberg N; Maier W; Mors O; Placentino A; Rietschel M; Souery D; Breen G; Curtis C; Sang-Hyuk L; Newhouse S; Patel H; Guipponi M; Perroud N; Bondolfi G; O'Donovan M; Lewis G; Biernacka JM; Weinshilboum RM; Farmer A; Aitchison KJ; Craig I; McGuffin P; Uher R; Lewis CM
Pharmacogenomics J; 2018 May; 18(3):413-421. PubMed ID: 29160301
[TBL] [Abstract][Full Text] [Related]
22. A prospective study to determine the clinical utility of pharmacogenetic testing of veterans with treatment-resistant depression.
McCarthy MJ; Chen Y; Demodena A; Leckband SG; Fischer E; Golshan S; Suppes T; Kelsoe JR
J Psychopharmacol; 2021 Aug; 35(8):992-1002. PubMed ID: 33938307
[TBL] [Abstract][Full Text] [Related]
23. The FKBP5-gene in depression and treatment response--an association study in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Cohort.
Lekman M; Laje G; Charney D; Rush AJ; Wilson AF; Sorant AJ; Lipsky R; Wisniewski SR; Manji H; McMahon FJ; Paddock S
Biol Psychiatry; 2008 Jun; 63(12):1103-10. PubMed ID: 18191112
[TBL] [Abstract][Full Text] [Related]
24. Replication of machine learning methods to predict treatment outcome with antidepressant medications in patients with major depressive disorder from STAR*D and CAN-BIND-1.
Nunez JJ; Nguyen TT; Zhou Y; Cao B; Ng RT; Chen J; Frey BN; Milev R; Müller DJ; Rotzinger S; Soares CN; Uher R; Kennedy SH; Lam RW
PLoS One; 2021; 16(6):e0253023. PubMed ID: 34181661
[TBL] [Abstract][Full Text] [Related]
25. IL6-174G > C genetic polymorphism influences antidepressant treatment outcome.
Carvalho S; Santos M; Lima L; Mota-Pereira J; Pimentel P; Maia D; Correia D; Gomes S; Cruz A; Medeiros R
Nord J Psychiatry; 2017 Feb; 71(2):158-162. PubMed ID: 27796193
[TBL] [Abstract][Full Text] [Related]
26. European Group for the Study of Resistant Depression (GSRD)--where have we gone so far: review of clinical and genetic findings.
Schosser A; Serretti A; Souery D; Mendlewicz J; Zohar J; Montgomery S; Kasper S
Eur Neuropsychopharmacol; 2012 Jul; 22(7):453-68. PubMed ID: 22464339
[TBL] [Abstract][Full Text] [Related]
27. Polygenic risk scores of lithium response and treatment resistance in major depressive disorder.
Xiong Y; Karlsson R; Song J; Kowalec K; Rück C; Sigström R; Jonsson L; Clements CC; Andersson E; Boberg J; Lewis CM; Sullivan PF; Landén M; Lu Y
Transl Psychiatry; 2023 Sep; 13(1):301. PubMed ID: 37770441
[TBL] [Abstract][Full Text] [Related]
28. The association of β-arrestin2 polymorphisms with response to antidepressant treatment in depressed patients.
Petit AC; El Asmar K; David DJ; Gardier AM; Becquemont L; Fève B; Verstuyft C; Corruble E
Prog Neuropsychopharmacol Biol Psychiatry; 2018 Feb; 81():74-79. PubMed ID: 29031912
[TBL] [Abstract][Full Text] [Related]
29. The impact of catechol-O-methyltransferase SNPs and haplotypes on treatment response phenotypes in major depressive disorder: a case-control association study.
Kocabas NA; Faghel C; Barreto M; Kasper S; Linotte S; Mendlewicz J; Noro M; Oswald P; Souery D; Zohar J; Massat I
Int Clin Psychopharmacol; 2010 Jul; 25(4):218-27. PubMed ID: 20531207
[TBL] [Abstract][Full Text] [Related]
30. Treatment response to low-dose ketamine infusion for treatment-resistant depression: A gene-based genome-wide association study.
Chen MH; Kao CF; Tsai SJ; Li CT; Lin WC; Hong CJ; Bai YM; Tu PC; Su TP
Genomics; 2021 Mar; 113(2):507-514. PubMed ID: 33370585
[TBL] [Abstract][Full Text] [Related]
31. Pharmacogenetics in major depression: a comprehensive meta-analysis.
Niitsu T; Fabbri C; Bentini F; Serretti A
Prog Neuropsychopharmacol Biol Psychiatry; 2013 Aug; 45():183-94. PubMed ID: 23733030
[TBL] [Abstract][Full Text] [Related]
32. Results of the European Group for the Study of Resistant Depression (GSRD) - basis for further research and clinical practice.
Bartova L; Dold M; Kautzky A; Fabbri C; Spies M; Serretti A; Souery D; Mendlewicz J; Zohar J; Montgomery S; Schosser A; Kasper S
World J Biol Psychiatry; 2019 Jul; 20(6):427-448. PubMed ID: 31340696
[No Abstract] [Full Text] [Related]
33. Common genetic variation and antidepressant efficacy in major depressive disorder: a meta-analysis of three genome-wide pharmacogenetic studies.
; ;
Am J Psychiatry; 2013 Feb; 170(2):207-17. PubMed ID: 23377640
[TBL] [Abstract][Full Text] [Related]
34. Relationship between FKBP5 polymorphisms and depression symptoms among kidney transplant recipients.
Shinozaki G; Jowsey S; Amer H; Biernacka J; Colby C; Walker D; Black J; Rundell J; Stegall M; Mrazek DA
Depress Anxiety; 2011 Dec; 28(12):1111-8. PubMed ID: 22134958
[TBL] [Abstract][Full Text] [Related]
35. The Impact of BDNF Polymorphisms on Suicidality in Treatment-Resistant Major Depressive Disorder: A European Multicenter Study.
Schosser A; Carlberg L; Calati R; Serretti A; Massat I; Spindelegger C; Linotte S; Mendlewicz J; Souery D; Zohar J; Montgomery S; Kasper S
Int J Neuropsychopharmacol; 2017 Oct; 20(10):782-787. PubMed ID: 28977521
[TBL] [Abstract][Full Text] [Related]
36. Phenotypic effects of a bipolar liability gene among individuals with major depressive disorder.
Casamassima F; Huang J; Fava M; Sachs GS; Smoller JW; Cassano GB; Lattanzi L; Fagerness J; Stange JP; Perlis RH
Am J Med Genet B Neuropsychiatr Genet; 2010 Jan; 153B(1):303-9. PubMed ID: 19388002
[TBL] [Abstract][Full Text] [Related]
37. Blood transcriptional response to treatment-resistant depression during electroconvulsive therapy.
Israel-Elgali I; Hertzberg L; Shapira G; Segev A; Krieger I; Nitzan U; Bloch Y; Pillar N; Mayer O; Weizman A; Gurwitz D; Shomron N
J Psychiatr Res; 2021 Sep; 141():92-103. PubMed ID: 34182381
[TBL] [Abstract][Full Text] [Related]
38. DISC1-TSNAX and DAOA genes in major depression and citalopram efficacy.
Arias B; Fabbri C; Serretti A; Drago A; Mitjans M; Gastó C; Catalán R; Fañanás L
J Affect Disord; 2014 Oct; 168():91-7. PubMed ID: 25043320
[TBL] [Abstract][Full Text] [Related]
39. The combined effect of genetic polymorphisms and clinical parameters on treatment outcome in treatment-resistant depression.
Kautzky A; Baldinger P; Souery D; Montgomery S; Mendlewicz J; Zohar J; Serretti A; Lanzenberger R; Kasper S
Eur Neuropsychopharmacol; 2015 Apr; 25(4):441-53. PubMed ID: 25769916
[TBL] [Abstract][Full Text] [Related]
40. Progress and prospects in pharmacogenetics of antidepressant drugs.
Fabbri C; Crisafulli C; Calabrò M; Spina E; Serretti A
Expert Opin Drug Metab Toxicol; 2016 Oct; 12(10):1157-68. PubMed ID: 27310483
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
